KPRX
KIORA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$2.76
+3.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.9%
- EBIT
- -17.7%
- EPS
- +23.7%
- Free cash flow
- -10.1%
- Operating cash flow
- -8.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +61.7%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026